studies on retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial The power of three: Retatrutide's

Avoid weight/obesity bias in deciding who should discontinue GLP-1RA therapy

Similarly, fatigue driven by thyroid dysfunction, anemia, adrenal insufficiency, or unmanaged depression requires treatment targeted at those conditions

Here are some common nutrient gaps to watch out for: The best way to get your daily nutrients is through food sources, though dietary supplementation can help support by bridging possible nutrient gaps

The pharmaceutical versions mimic this hormone, plus a few others (GIP and glucagon)

Cardiovascular benefits are based on surrogate markers

This suggests that GLP-1 RAs may directly influence these areas, thereby affecting emotional and behavioral states [81]